Aude C.
- Country
- France
- Department
- Ophthalmology
Research Overview
- Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
- Evaluation of Ranibizumab Port Delivery System Refill Regimens in Neovascular Age-Related Macular Degeneration: A Phase IIIb Randomized Study
- Evaluation of Fluocinolone Acetonide Versus Dexamethasone Intravitreal Implants in Resistant Diabetic Macular Edema in Pseudophakic Patients
Data & Insights
Has run more than one trial at 105 of 175 partner sites.
Specializations
Age-Related Macular Degeneration
The investigator specializes in treating advanced forms of age-related macular degeneration (AMD), with particular focus on both neovascular AMD and geographic atrophy. Their research encompasses innovative delivery systems and therapeutic approaches for managing these conditions.
- Neovascular AMD Treatment
- Geographic Atrophy Management
- Port Delivery System Applications
Works with novel therapeutic agents including ranibizumab delivery systems and complement inhibitors for AMD treatment.
Diabetic Eye Disease
Focuses on the treatment of diabetic macular edema (DME), investigating various therapeutic approaches including corticosteroid implants and novel drug delivery methods.
- Intravitreal Implant Therapies
- Long-term DME Management
- Treatment-resistant Cases
Evaluates comparative effectiveness of different treatment modalities in diabetic eye conditions.
Advanced Therapeutics
Investigates cutting-edge treatments including gene therapy and novel pharmaceutical compounds for retinal diseases. Specializes in innovative drug delivery mechanisms and long-term disease management strategies.
- Sustained Release Technologies
- Complement Inhibition Therapy
- Intravitreal Administration Methods
Explores new therapeutic pathways and treatment protocols for retinal conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.